Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
RESEARCH TOOLSreports
DBV Technologies SA - American (DBVT) Stock Price & Analysis
352 Followers
DBVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $3.70
Previous Close$0.84
Volume96.35K
Average Volume (3M)84.63K
Market Cap
$82.92M
Enterprise Value-$52.77M
Total Cash (Recent Filing)$141.37M
Total Debt (Recent Filing)$5.67M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Jul 29, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding96,434,369
10 Day Avg. Volume188,362
30 Day Avg. Volume84,631
Standard Deviation0.27
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.67
Price to Sales (P/S)5.95
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.36
Enterprise Value/Gross Profit-3.36
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$6.43Price Target Upside666.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
DBV Technologies SA - American News
PremiumCompany Announcements
DBV Technologies Announces ADS Ratio Change and Issues Notice
PremiumCompany Announcements
DBV Technologies SA Announces ADS Ratio Adjustment and Market StrategyBulls Say, Bears Say
Bulls Say
Product PotentialViaskin, if approved, has the potential to corner the peanut allergy market.
Regulatory ExpertiseDBT Technologies has brought in Robert Pietrusko as its Chief Regulatory Officer, who has extensive regulatory expertise.
Trial ProgressThe Phase 3 VITESSE trial passes the halfway enrollment point, remaining on track to complete enrollment in 3Q24, with top-line data slated for 3Q25.
Bears Say
Cash FlowWith current cash only expected to fund planned operations till December 2024, it is critical that the focus remains on getting Viaskin across the finish line in the toddler population (1-3 years).
Financial Performance1Q24 OpEx of $30M was above the $22M estimate, largely due to higher-than-anticipated R&D expenses of $21M.
Product AdoptionXolair’s black box warning for anaphylaxis and steep price might limit its adoption.
---
Ownership Overview
30.45% Insiders
0.55% Mutual Funds
0.06% Other Institutional Investors
68.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $0.50 and its highest was $3.70 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
Currently, no data Available
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Jul 29, 2024 which is in 22 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on May 07, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.14.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -$0.45.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 96,493,080 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 2.206%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Among the largest hedge funds holding DBV Technologies SA - American’s share is Baker Bros Advisors LP. It holds DBV Technologies SA - American’s shares valued at 11M.
---
DBV Technologies SA - American Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.43 (666.57% Upside)
$6.43 (666.57% Upside)
Hedge Fund Trend
Increased
By 3.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.10%
12-Months-Change
Fundamentals
Return on Equity
-54.69%
Trailing 12-Months
Asset Growth
-37.36%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
---
DBVT Earnings Call
Q4 2024
0:00 / 0:00
---
DBVT Stock 12 Month Forecast
Average Price Target
$6.43
▲(666.57% Upside)
Technical Analysis
Best Analysts Covering DBVT
1 Year
1 Year Success Rate
5/21 ratings generated profit
1 Year Average Return
-29.59%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -29.59% per trade.
---